Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-03-10

Clinical Trial Update: Ipilimumab + Temozolomide in Metastatic Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of ipilimumab and temozolomide in metastatic melanoma has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Temodar (Temozolomide)
  • Yervoy (ipilimumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2020-03-10